American Society of Clinical Oncology (ASCO)

UK-led phase III trial reports similar disease control at 12 months versus two years of immunotherapy for inoperable late-stage…

​​​First and only EGFR inhibitor and targeted treatment to show benefit in stage III setting, extending progression-free survival…